Prosomnus_logo_Horizontal_V3.png
ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization
07 août 2024 17h30 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting
13 mai 2024 09h00 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
09 mai 2024 18h30 HE | ProSomnus Sleep Technologies, Inc.
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success
08 mai 2024 20h53 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
22 févr. 2024 08h30 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
30 janv. 2024 08h00 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
29 janv. 2024 08h00 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
08 janv. 2024 08h00 HE | ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
Apnimed.png
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 déc. 2023 08h30 HE | Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...